Provided by Tiger Trade Technology Pte. Ltd.

Longeveron Inc

0.5751
+0.01512.70%
Post-market: 0.5650-0.0101-1.76%19:56 EST
Volume:48.28K
Turnover:27.29K
Market Cap:12.27M
PE:-0.43
High:0.5800
Open:0.5600
Low:0.5480
Close:0.5600
52wk High:1.92
52wk Low:0.4920
Shares:21.33M
Float Shares:16.75M
Volume Ratio:0.56
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3485
EPS(LYR):-2.6164
ROE:-119.92%
ROA:-60.95%
PB:1.23
PE(LYR):-0.22

Loading ...

Longeveron Appoints New CEO Amid Cost-Cutting Initiatives

TIPRANKS
·
Feb 14

Longeveron Appoints Stephen Willard as CEO

MT Newswires Live
·
Feb 14

Longeveron Names Stephen H. Willard as Chief Executive Officer

Reuters
·
Feb 14

Longeveron Inc - Than Powell Steps Down as Interim CEO

THOMSON REUTERS
·
Feb 14

Longeveron Inc: Phase 2B Clinical Trial in Hypoplastic Left Heart Syndrome Anticipated in Q3 of 2026

THOMSON REUTERS
·
Feb 14

Press Release: Longeveron(R) Appoints Stephen H. Willard as Chief Executive Officer

Dow Jones
·
Feb 14

Longeveron ‘applauds’ Mikaela Naylon Give Kids a Chance Act passage

TIPRANKS
·
Feb 05

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

GlobeNewswire
·
Feb 05

Longeveron granted Japan patent for potency assay methods for MSCs

TIPRANKS
·
Jan 29

Longeveron Granted Japan Patent for Potency Assay Methods for Human Mesenchymal Stem Cells

Reuters
·
Jan 29

Longeveron granted FDA Type C Meeting ahead of ELPIS II data readout

TIPRANKS
·
Jan 26

Longeveron Inc - Elpis Ii Trial Results Anticipated in Q3 2026

THOMSON REUTERS
·
Jan 26

Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

GlobeNewswire
·
Jan 26

Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026

GlobeNewswire
·
Dec 29, 2025

Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using Its Proprietary Stem Cell Therapy

THOMSON REUTERS
·
Dec 17, 2025

Longeveron Granted U.S. Patent for Stem Cell Therapy to Treat Female Sexual Dysfunction

Reuters
·
Dec 17, 2025

Longeveron Executives Speak at Global CardioVascular Clinical Trialists Forum

Reuters
·
Dec 03, 2025

Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global Cardiovascular Clinical Trialists (Cvct) Forum

THOMSON REUTERS
·
Dec 03, 2025

Longeveron Granted Canadian Patent for Stem Cell Therapy Targeting Aging-Related Frailty and Cardiomyopathy

Reuters
·
Dec 02, 2025

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-Related Frailty in Patients With Inflammaging

THOMSON REUTERS
·
Dec 02, 2025